These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38634132)

  • 1. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
    Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
    Solimani F; Meier K; Ghoreschi K
    Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.
    Nystrom SE; Li G; Datta S; Soldano KL; Silas D; Weins A; Hall G; Thomas DB; Olabisi OA
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35472001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
    Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
    Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Adapted SARS-CoV-2 (MA10) Viral Infection Induces Neuroinflammation in Standard Laboratory Mice.
    Amruta N; Ismael S; Leist SR; Gressett TE; Srivastava A; Dinnon KH; Engler-Chiurazzi EB; Maness NJ; Qin X; Kolls JK; Baric RS; Bix G
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
    Akbarzadeh-Khiavi M; Torabi M; Rahbarnia L; Safary A
    Infection; 2022 Apr; 50(2):295-308. PubMed ID: 34902115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
    Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
    Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
    EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib set to join the Covid-19 therapeutic arsenal?
    Gudu T; Stober C; Cope AP; Cheriyan J; Galloway J; Wilkinson IB; Kostapanos M; Jayne D; Hall F
    Rheumatology (Oxford); 2021 Apr; 60(4):1585-1587. PubMed ID: 33502499
    [No Abstract]   [Full Text] [Related]  

  • 15. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
    Spinelli FR; Conti F; Gadina M
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 infection causes a decline in renal megalin expression and affects vitamin D metabolism in the kidney of K18-hACE2 mice.
    Kurosaki Y; Matsumoto T; Uematsu T; Kawakami F; Kawashima R; Tamaki S; Imai M; Ichikawa T; Ishii N; Kitasato H; Hanaki H; Kubo M
    Sci Rep; 2024 Oct; 14(1):24313. PubMed ID: 39414885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions.
    Omer D; Pleniceanu O; Gnatek Y; Namestnikov M; Cohen-Zontag O; Goldberg S; Friedman YE; Friedman N; Mandelboim M; Vitner EB; Achdout H; Avraham R; Zahavy E; Israely T; Mayan H; Dekel B
    J Am Soc Nephrol; 2021 Sep; 32(9):2242-2254. PubMed ID: 34112705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice.
    Thieulent CJ; Dittmar W; Balasuriya UBR; Crossland NA; Wen X; Richt JA; Carossino M
    mSphere; 2023 Feb; 8(1):e0055822. PubMed ID: 36728430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.